3D Bioprinting Market - By Component (Microextrusion, Inkjet, and Laser), By Bioink (Natural, Synthetic, and Hybrid), By Material (Hydrogen and Living Cells), By Application (Skin and Drug Research), End-Use (Biopharma and Academia), and By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

3D Bioprinting Market size accounted 781.92 million in 2020 is estimated to reach 4841.443 million by 2030 growing with a CAGR of 20% during the forecast period.Bioprinting works in a similar way to conventional 3D printing that includes biomaterials such as cells; growth factors are combined to create tissue-like structures that imitate natural tissues. 3D printing is the technique to fabricate biomedical parts that maximally imitate natural tissue characteristics. The technology uses a bioink to create these structures in a layer by layer manner. Three-dimensional 3D bioprinting, is an art technology to fabricate biological constructs with hierarchical architecture similar to their native counterparts. Developing living functional tissues by artificial means can address an unmet need in tissue replacement and organ transplantation.

Market Segmentation:

The global 3D bioprinting market is segmented on the basis of material; into hydrogels, extracellular matrices, living cells, and other biomaterials. Based on components, the market is classified into microextrusion, inkjet, and lasers. On the basis of the application, the 3D bioprinting market is segmented into skin bioprinting, drug research, and others. By end-user, the market is categorized into biopharma and academics. On the basis of region, the 3D bioprinting market is divided into North America, Europe, Asia-Pacific, and RoW.

Market Dynamics and Factors:

The technological advancements in 3D bioprinters and biomaterials, increasing use of 3D bioprinting in the pharmaceutical and cosmetology industries, and rising public and private funding to support bioprinting research activities is driving the global 3D bioprinting market.  3D bioprinting technology observed increased adoption in the healthcare industry. Bioprinting has emerged as a promising technology for the fabrication of artificial tissues and organs, which can revolutionize the diagnosis and treatment of various medical conditions. Bioprinting companies around the world are continuously innovating in medicine, tissue engineering, drug therapies, and stem cell therapy, which are attracting attention from healthcare professionals and pharmaceutical companies to visualize a future with better patient care, customized medical treatment, and an alternative to organ transplantation. But these technologies and processes require the skills of a trained professional who can understand and operate the 3D bioprinter. Increasing stem cell research activities and financial support from several private organizations are driving the 3D bioprinting market growth of the stem cell and regenerative medicine industry across the globe. The use of bioprinted products inside the human body creates biosafety concerns and can also violate religious beliefs. Additionally, the source of biomaterials being used for developing 3D bioprinted products and concerns related to waste elimination are two other major factors hindering the adoption of 3D bioprinting among individuals. This can challenge the market growth.

Geographic Analysis:

North America is dominating the region in the global 3D bioprinting market due to technological advancement and owing to demand for 3D products, presence of various additive manufacturers, and high disposable income levels of patients. The region accounted to contribute the largest market share in terms of revenue in 2019 and is anticipated to demonstrate the same supremacy in the upcoming years. The Asia Pacific market is anticipated to grow at the fastest CAGR of 22.1% during the forecast period, driven by the increasing research activities, growing demand for organ transplants, an increasing number of initiatives by market players for expanding their presence in the APAC, and higher adoption of stem cell research in several APAC countries. Europe is expected to offer significant growth opportunities for players operating in the 3D bioprinting industry, owing to the growing support from government bodies, increasing demand for cosmetic surgeries, and the presence of less-stringent regulations and data requirements (as compared to developed countries) in their respective healthcare systems.

Competitive Scenario:

The major players include in the 3D bioprinting industry are Allevi Inc, Aspect Biosystem, Envision Tec GMBH, Cyfuse Biomedical KK, Poietis, Nano 3D biosciences Inc, Rokit Healthcare, Digilab, RegenHU, GeSim, Regenovo biotechnology, and Tevido Biodevices.

3D Bioprinting Market Report Scope